AU2020290484A1 - Modified dosage of subcutaneous tocilizumab for rheumatoid arthritis - Google Patents

Modified dosage of subcutaneous tocilizumab for rheumatoid arthritis Download PDF

Info

Publication number
AU2020290484A1
AU2020290484A1 AU2020290484A AU2020290484A AU2020290484A1 AU 2020290484 A1 AU2020290484 A1 AU 2020290484A1 AU 2020290484 A AU2020290484 A AU 2020290484A AU 2020290484 A AU2020290484 A AU 2020290484A AU 2020290484 A1 AU2020290484 A1 AU 2020290484A1
Authority
AU
Australia
Prior art keywords
subject
administered
tocilizumab
antibody
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020290484A
Other languages
English (en)
Inventor
Chieh-I CHEN
Wenhui WEI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of AU2020290484A1 publication Critical patent/AU2020290484A1/en
Assigned to SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC. reassignment SANOFI BIOTECHNOLOGY Request for Assignment Assignors: CHEN, Chieh-I, REGENERON PHARMACEUTICALS, INC., SANOFI BIOTECHNOLOGY, WEI, Wenhui
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020290484A 2019-06-12 2020-06-11 Modified dosage of subcutaneous tocilizumab for rheumatoid arthritis Abandoned AU2020290484A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962860611P 2019-06-12 2019-06-12
US62/860,611 2019-06-12
EP20305192.5 2020-02-27
EP20305192 2020-02-27
PCT/US2020/037325 WO2020252214A1 (en) 2019-06-12 2020-06-11 Modified dosage of subcutaneous tocilizumab for rheumatoid arthritis

Publications (1)

Publication Number Publication Date
AU2020290484A1 true AU2020290484A1 (en) 2021-12-23

Family

ID=71170831

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020290484A Abandoned AU2020290484A1 (en) 2019-06-12 2020-06-11 Modified dosage of subcutaneous tocilizumab for rheumatoid arthritis

Country Status (13)

Country Link
US (1) US20220242959A1 (https=)
EP (1) EP3983071A1 (https=)
JP (2) JP2022536739A (https=)
KR (1) KR20230047944A (https=)
CN (1) CN115003382A (https=)
AU (1) AU2020290484A1 (https=)
BR (1) BR112021025060A2 (https=)
CA (1) CA3143261A1 (https=)
CO (1) CO2022000064A2 (https=)
IL (1) IL288690A (https=)
MA (1) MA56190A (https=)
MX (1) MX2021015336A (https=)
WO (1) WO2020252214A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
CN115825415B (zh) * 2022-09-28 2023-07-14 珠海重链生物科技有限公司 阻断剂和体外免疫诊断产品、应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
KR20190120439A (ko) * 2010-11-08 2019-10-23 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체

Also Published As

Publication number Publication date
BR112021025060A2 (pt) 2022-02-22
JP2026032195A (ja) 2026-02-25
MX2021015336A (es) 2022-10-21
JP2022536739A (ja) 2022-08-18
WO2020252214A1 (en) 2020-12-17
IL288690A (en) 2022-02-01
KR20230047944A (ko) 2023-04-10
CN115003382A (zh) 2022-09-02
CA3143261A1 (en) 2020-12-17
CO2022000064A2 (es) 2022-04-08
US20220242959A1 (en) 2022-08-04
EP3983071A1 (en) 2022-04-20
MA56190A (fr) 2022-04-20

Similar Documents

Publication Publication Date Title
AU2011312623B2 (en) Anti-CD48 antibodies and uses thereof
US20200017599A1 (en) ANTI-C5a RECEPTOR ANTIBODIES
US9809647B2 (en) Neutralizing anti-CCL20 antibodies
JP2019503363A (ja) 急性リンパ芽球性白血病を治療するための二重特異性の抗ｃｄ２０／抗ｃｄ３抗体
JP2026032195A (ja) 関節リウマチのための皮下トシリズマブの改良された投薬量
IL293288A (en) Methods for the treatment of multiple myeloma with bispecific anti-bcma and anti-cd3 antibodies
JP2022518588A (ja) 抗ｐｄ－１抗体、その抗原結合フラグメントおよびそれらの医薬用途
US20250333522A1 (en) Compositions and methods for treating pain in subjects with rheumatoid arthritis
KR20210122810A (ko) 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
CA3107186A1 (en) Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
JP2024526414A (ja) Ｉｌ－６ｒアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法
US20230192871A1 (en) Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis
CA3180369A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
US20180208656A1 (en) Anti-Prokineticin Receptor (PROKR) Antibodies and Uses Thereof
US20250137065A1 (en) Predictive Biomarkers in Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
TW202547482A (zh) 已接受類固醇之具有風濕性多肌痛症之個體之治療
CA3244791A1 (en) Dosages for the mitigation of cytokine release syndrome with Odronextamab

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SANOFI BIOTECHNOLOGY

Free format text: FORMER APPLICANT(S): REGENERON PHARMACEUTICALS, INC.; SANOFI BIOTECHNOLOGY; WEI, WENHUI; CHEN, CHIEH-I

Owner name: REGENERON PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): REGENERON PHARMACEUTICALS, INC.; SANOFI BIOTECHNOLOGY; WEI, WENHUI; CHEN, CHIEH-I

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted